Navigation Links
TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients

SCOTTSDALE, Ariz. -- Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new drug combination consisting of a standard drug called gemcitabine and a drug called nab-paclitaxel for patients with advanced pancreatic cancer.

The results of this study, headed by renowned pancreatic cancer expert Dr. Daniel Von Hoff, were published online Oct. 3, 2011, in the prestigious Journal of Clinical Oncology.

Nab-paclitaxel (Abraxane), an albumin-bound formulation of paclitaxel, is a drug manufactured by Abraxis BioScience a wholly-owned subsidiary of Celgene and is approved for the treatment of patients with advanced breast cancer. The use of this agent in patients with pancreatic cancer is investigational.

Virginia G. Piper Cancer Center Clinical Trials is a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) to rapidly bring new discoveries in the laboratory to patients.

"This is a great example of rapid bench to bedside development," said Dr. Von Hoff, TGen's Physician-In-Chief and Chief Scientific Officer for the Scottsdale Healthcare Research Institute.

Scientists at TGen and the International Genomics Consortium, in collaboration with Abraxis scientists, found that in pancreatic cancer an albumin-binding protein called SPARC was present at high levels in cells within the pancreatic tumor microenvironment. It was hypothesized that the albumin formulation of nab-paclitaxel may be taken up by tumor cells with high SPARC expression. Based on these findings, Dr. Von Hoff -- joined by colleagues from Johns Hopkins University Hospital, Baltimore; University of Alabama, Birmingham; and South Texas Oncology-Hematology, San Antonio -- conducted a clinical trial in patients with advanced pancreatic cancer.

The results of this pilot study in which 67 patients were treated showed impressive results. Following completion of a safety and dose finding phase, 44 patients were treated in the phase II group. About half the patients showed reductions in tumor size measured by CT scans, and about 50 percent lived at least a year.

"Compared to the average survival of 6 months seen typically in this group of patients, this is very encouraging," said Dr. Ramesh Ramanathan, medical director, Virginia G. Piper Cancer Center Clinical Trials. He added that the results of this study need to be confirmed. A large worldwide study of 842 patients comparing the standard treatment of gemcitabine to the new regimen of gemcitabine and nab paclitaxel is underway, led by Dr. Von Hoff and Dr. Ramanathan.

According to Dr. Ron Korn, the lead radiologist and a co-author on this paper, the study also provided important information on the role of PET scans. "If we can find early in the course of treatment if a patient will respond to treatment or not, then we can change course quickly, this study showed that patients who had a decrease in intensity of 'hot spots' on a PET scan after 6 weeks of treatment were more likely to have a good outcome." Dr. Korn added that this approach is being further investigated in clinical trials with targeted agents in collaboration with the Virginia G. Piper Cancer Center.

Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713 or via email at

Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. TGen, Virginia G. Piper Cancer Center studying new breast cancer drug
2. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
3. Enhancing arrest of cell growth to treat cancer in mice
4. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
5. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
6. Low forms of cyclin E reduce breast cancer drugs effectiveness
7. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
8. Soft drinks may increase risk of pancreatic cancer
9. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
10. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
11. Single gene mutation induces endometrial cancer
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology: